Ridogrel inhibits systemic and renal formation of thromboxane-a2 and antagonizes platelet thromboxane-a2 prostaglandin endoperoxide receptors upon chronic administration to man

The effects of ridogrel, a dual thromboxane A 2 (TXA 2 ) synthase inhibitor and TXA 2 /prostaglandin (PG) endoperoxide receptor antagonist, on systemic and renal production of prostaglandins and on platelet TXA 2 /PG endoperoxide receptors was evaluated upon chronic administration (300 mg b.i.d. orally, for 8 and 29 days) to man